Lake Street lowered the firm’s price target on Ekso Bionics (EKSO) to $1 from $2 and keeps a Buy rating on the shares. Q4 results were “a touch better than we had modeled,” and although the firm now sees lower revenue this year, it expects an improved 2026 on “a smoother, more repeatable reimbursement process” for patients acquiring Indego Personal units, the analyst tells investors in a post-earnings note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EKSO:
- Ekso Bionics: Strategic Partnerships and Financial Health Drive Buy Rating with $9 Price Target
- Ekso Bionics Reports Record Q4 Revenue and Strategic Partnership
- Ekso Bionics reports Q4 EPS (14c) vs. (22c) last year
- EKSO Upcoming Earnings Report: What to Expect?
- Ekso Bionics names NSM as Ekso Indego Personal device distributor
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue